<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Top 15 Pharma & Biotech M&A Deals of Q1 2024</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            background-color: #f4f4f4;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            background-color: #fff;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        th, td {
            padding: 12px;
            text-align: left;
            border-bottom: 1px solid #ddd;
        }
        th {
            background-color: #4a90e2;
            color: white;
        }
        tr:nth-child(even) {
            background-color: #f8f8f8;
        }
        tr:hover {
            background-color: #e0e0e0;
        }
        caption {
            font-size: 1.5em;
            font-weight: bold;
            margin-bottom: 10px;
            color: #333;
        }
    </style>
</head>
<body>
    <table>
        <caption>Top 15 Pharma & Biotech M&A Deals of Q1 2024 (in USD Billion)</caption>
        <tr>
            <th>Acquiring Company</th>
            <th>Acquired Company</th>
            <th>Value (USD Billion)</th>
        </tr>
        <tr>
            <td>Novo Holdings</td>
            <td>Catalent</td>
            <td>$16.50B</td>
        </tr>
        <tr>
            <td>Gilead</td>
            <td>CymaBay</td>
            <td>$4.30B</td>
        </tr>
        <tr>
            <td>Sinopharm</td>
            <td>[Not specified]</td>
            <td>$3.00B</td>
        </tr>
        <tr>
            <td>Novartis</td>
            <td>MorphoSys</td>
            <td>$2.90B</td>
        </tr>
        <tr>
            <td>Roquette</td>
            <td>IFF Pharma Solutions</td>
            <td>$2.85B</td>
        </tr>
        <tr>
            <td>AstraZeneca</td>
            <td>Fusion</td>
            <td>$2.41B</td>
        </tr>
        <tr>
            <td>Sanofi</td>
            <td>Inhibrx</td>
            <td>$2.20B</td>
        </tr>
        <tr>
            <td>Johnson & Johnson</td>
            <td>Ambrx</td>
            <td>$2.00B</td>
        </tr>
        <tr>
            <td>ALPS</td>
            <td>Globelink</td>
            <td>$1.60B</td>
        </tr>
        <tr>
            <td>GSK</td>
            <td>Aiolos Bio</td>
            <td>$1.40B</td>
        </tr>
        <tr>
            <td>MSD Animal Health</td>
            <td>Elanco</td>
            <td>$1.30B</td>
        </tr>
        <tr>
            <td>Lonza</td>
            <td>GeneTech</td>
            <td>$1.20B</td>
        </tr>
        <tr>
            <td>Cardinal Health</td>
            <td>Specialty Networks</td>
            <td>$1.20B</td>
        </tr>
        <tr>
            <td>Novo Nordisk</td>
            <td>Cardior</td>
            <td>$1.11B</td>
        </tr>
        <tr>
            <td>AstraZeneca</td>
            <td>AmolyT Pharma</td>
            <td>$1.05B</td>
        </tr>
    </table>
</body>
</html>